Trial Profile
A PHASE II STUDY Of ADJUVANT CHEMOTHERAPY After SURGERY For STAGE I Lung ADENOCARCINOMA PATIENTS With MICROPAPILLARY COMPONENT More Than Or EQUAL To 20%
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Dec 2017 Planned number of patients changed from 540 to 460.
- 14 Dec 2017 Planned number of patients changed from 200 to 540.
- 27 Nov 2017 New trial record